Physician profile
Seema Kumar
NPI 1396760393
$4,316.63
in general payments reported to CMS, 2019-2025
17 companies · $889 in 2025
The $889 reported for 2025 was more than what 84% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,401 · 2020: $32.62 · 2021: $13.97 · 2022: $117 · 2023: $962 · 2024: $901 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,752.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $950.97 | 2019-2025 | Rexulti |
| Alkermes, INC. | $409.79 | 2023-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $350.66 | 2023-2024 | Auvelity |
| Corium, LLC | $348.69 | 2022-2025 | Azstarys |
| Noven Therapeutics, LLC | $295.91 | 2024-2025 | Xelstrym |
| Sunovion Pharmaceuticals INC. | $288.35 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $287.32 | 2022-2024 | Caplyta |
| Tris Pharma INC | $251.20 | 2022-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Ironshore Pharmaceuticals INC. | $246.14 | 2019-2024 | |
| Lundbeck LLC | $232.85 | 2023-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $180.66 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $147.97 | 2019 | |
| Shire North American Group INC | $121.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.88 | 2024-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $64.12 | 2024 | Cobenfy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $24.63 | 2025 | Relexxii |
| Adlon Therapeutics L.P. | $18.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seema Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.